News

Oncolytics Biotech, a biopharmaceutical company, has completed patient enrollment in its UK clinical trial to evaluate the anti-tumor effects of intravenous administration of Reolysin in combination with gemcitabine

Patheon and Swiftwater will combine resources to provide regulatory consulting services to clients. Swiftwater Group can assist Patheon clients as they navigate through the regulatory process, by providing

Adventrx Pharmaceuticals, a biopharmaceutical company, has granted Shin Poong Pharmaceutical exclusive rights in South Korea to make, use and sell ANX-514, one of its two lead product candidates.

Ms Eastham will join Geron’s existing board members: board chair Alexander Barkas, Edward Fritzky, Charles Homcy, Thomas Kiley, Patrick Zenner and Geron’s president and CEO, Thomas Okarma. Ms

The new round of funding includes participation from Forbion Capital Partners, HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners, Giza Venture Capital and individual investors. Pathway will

Xcellerex, a developer and marketer of biomolecules, along with three collaborators, has received an $11 million Phase II contract from the Defense Threat Reduction Agency – Joint Science

SGN-35, an antibody-drug conjugate, is in an ongoing pivotal trial under a special protocol assessment from the FDA for relapsed or refractory Hodgkin lymphoma. The designation allows the

Ixiaro was developed to provide a well-tolerated, effective and convenient vaccine against Japanese encephalitis (JE), suitable for administration to travelers who wish to reduce their risk of acquiring

The topiramate tablets are therapeutically equivalent to Topamax tablets from Ortho-McNeil Janssen Pharmaceuticals and are available in four strengths: 25mg, 50mg, 100mg and 200mg. Topiramate is indicated as